A Randomized Phase I/II Trial Using a GM-CSF-Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L) Vaccine in Combination With CCL21 for Patients With Stage IV Adenocarcinoma of the Lung
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 13 Jun 2018
At a glance
- Drugs CD40L GVAX (Primary) ; Cancer vaccine
- Indications Adenocarcinoma; Lung cancer
- Focus Adverse reactions; Therapeutic Use
- 10 May 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 08 Dec 2017 Planned End Date changed from 28 Feb 2018 to 1 Dec 2018.
- 25 Jul 2017 Planned End Date changed from 31 Dec 2017 to 28 Feb 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History